Sato Takehito, Nishiwaki Kimitoshi
Anesthesiology, Nagoya University Hospital, Nagoya, JPN.
Anesthesiology, Nagoya University Graduate School of Medicine, Nagoya, JPN.
Cureus. 2024 Sep 13;16(9):e69311. doi: 10.7759/cureus.69311. eCollection 2024 Sep.
Anesthetic management for awake craniotomy (AC) often poses problems in patients with obesity including respiratory management. The Japan Awake Craniotomy Guidelines state that the indication for surgery should be carefully considered, especially in patients with obesity (body mass index (BMI) > 30). Patients with obesity often have comorbidities such as dyslipidemia, hypertension, and type 2 diabetes, and this is a risk factor for perioperative morbidity and mortality. Remimazolam, a new intravenous anesthetic, has been reported to be useful in anesthesia management during AC, but its use in obese patients has not been reported. Herein, we report two cases case series in which remimazolam was used in patients with obesity and safely managed under anesthesia with the pharmacokinetic simulations.
清醒开颅手术(AC)的麻醉管理在肥胖患者中常常会带来包括呼吸管理在内的诸多问题。《日本清醒开颅手术指南》指出,对于手术适应症应仔细考量,尤其是在肥胖患者(体重指数(BMI)>30)中。肥胖患者常伴有血脂异常、高血压和2型糖尿病等合并症,这是围手术期发病和死亡的危险因素。瑞米唑仑是一种新型静脉麻醉药,据报道其在AC麻醉管理中有用,但尚未见其在肥胖患者中应用的报道。在此,我们报告两例使用瑞米唑仑的肥胖患者病例系列,通过药代动力学模拟在麻醉下实现了安全管理。